1. Home
  2. TTGT vs ABVX Comparison

TTGT vs ABVX Comparison

Compare TTGT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TTGT
  • ABVX
  • Stock Information
  • Founded
  • TTGT 1999
  • ABVX 2013
  • Country
  • TTGT United States
  • ABVX France
  • Employees
  • TTGT N/A
  • ABVX N/A
  • Industry
  • TTGT Telecommunications Equipment
  • ABVX
  • Sector
  • TTGT Telecommunications
  • ABVX
  • Exchange
  • TTGT Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • TTGT 810.0M
  • ABVX 722.3M
  • IPO Year
  • TTGT 2007
  • ABVX N/A
  • Fundamental
  • Price
  • TTGT $20.07
  • ABVX $7.91
  • Analyst Decision
  • TTGT Strong Buy
  • ABVX Strong Buy
  • Analyst Count
  • TTGT 6
  • ABVX 6
  • Target Price
  • TTGT $38.17
  • ABVX $38.67
  • AVG Volume (30 Days)
  • TTGT 314.5K
  • ABVX 123.5K
  • Earning Date
  • TTGT 02-05-2025
  • ABVX 09-09-2024
  • Dividend Yield
  • TTGT N/A
  • ABVX N/A
  • EPS Growth
  • TTGT N/A
  • ABVX N/A
  • EPS
  • TTGT N/A
  • ABVX N/A
  • Revenue
  • TTGT $260,750,999.00
  • ABVX $9,676,417.00
  • Revenue This Year
  • TTGT $1.57
  • ABVX $31.67
  • Revenue Next Year
  • TTGT $6.46
  • ABVX $1,189.66
  • P/E Ratio
  • TTGT N/A
  • ABVX N/A
  • Revenue Growth
  • TTGT N/A
  • ABVX 100.87
  • 52 Week Low
  • TTGT $19.73
  • ABVX $7.11
  • 52 Week High
  • TTGT $41.93
  • ABVX $17.02
  • Technical
  • Relative Strength Index (RSI)
  • TTGT 32.12
  • ABVX 40.45
  • Support Level
  • TTGT $19.57
  • ABVX $7.11
  • Resistance Level
  • TTGT $28.44
  • ABVX $8.18
  • Average True Range (ATR)
  • TTGT 2.33
  • ABVX 0.44
  • MACD
  • TTGT -0.76
  • ABVX -0.00
  • Stochastic Oscillator
  • TTGT 10.58
  • ABVX 44.24

About TTGT TechTarget Inc.

TechTarget Inc is a data, software and analytics leader for purchase intent-driven marketing and sales data which delivers business impact for business-to-business (B2B) companies. The company solutions are designed to enable B2B technology companies to identify, reach, and influence key enterprise technology decision makers faster and with higher efficacy. Geographically, it derives a majority of its revenue from North America. Its products and services intended to improve information technology vendors abilities to impact targeted audiences for business growth using targeting, first-party analytics and data services complemented with customized marketing programs that integrate content creation, demand generation, brand marketing, and other advertising techniques.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Share on Social Networks: